ABI-011

DRUG2 trials

Sponsors

Celgene, NantBioScience, Inc.

Conditions

Advanced Solid TumorsNeoplastic Disease

Phase 1

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

TerminatedNCT01163071

CelgeneAdvanced Solid Tumors

Start: 2011-03-01End: 2011-09-23Target: 60Updated: 2019-11-14

QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas

WithdrawnNCT02582827

NantBioScience, Inc.Neoplastic Disease

Start: 2017-11-13End: 2019-08-23Updated: 2019-08-28